Mereo BioPharma Group plc (LON:0A9G)
London
· Delayed Price · Currency is GBP · Price in USD 2.805
-0.014 (-0.50%)
At close: Jun 20, 2025
Mereo BioPharma Group Income Statement
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | 2015 - 2019 |
|---|---|---|---|---|---|---|---|
Period Ending | Mar '25 Mar 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | 2015 - 2019 |
| Revenue | - | - | 10 | - | 49.37 | - | Upgrade
|
| Cost of Revenue | - | - | 2.57 | -1.15 | 24.25 | - | Upgrade
|
| Gross Profit | - | - | 7.43 | 1.15 | 25.13 | - | Upgrade
|
| Selling, General & Admin | 27.8 | 26.43 | 18.42 | 26.11 | 21.57 | 28.97 | Upgrade
|
| Research & Development | 19.51 | 19.28 | 16.14 | 27.74 | 31.9 | 22.32 | Upgrade
|
| Operating Expenses | 47.31 | 45.72 | 34.56 | 53.84 | 53.47 | 51.29 | Upgrade
|
| Operating Income | -47.31 | -45.72 | -27.14 | -52.7 | -28.35 | -51.29 | Upgrade
|
| Interest Expense | -1.24 | -1.37 | -2.88 | -4.18 | -5.11 | -8.5 | Upgrade
|
| Interest & Investment Income | 3.08 | 3.04 | 2.13 | 0.84 | 0 | 0.01 | Upgrade
|
| Currency Exchange Gain (Loss) | -2.17 | 1.21 | -2.35 | 2.72 | -1.29 | -2.49 | Upgrade
|
| Other Non Operating Income (Expenses) | 0.45 | -0.42 | 0.24 | 10.37 | 53.88 | -150.19 | Upgrade
|
| EBT Excluding Unusual Items | -47.19 | -43.25 | -30 | -42.94 | 19.13 | -212.46 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | - | - | 0.05 | Upgrade
|
| Gain (Loss) on Sale of Assets | - | - | - | - | 0.15 | -14.84 | Upgrade
|
| Pretax Income | -47.19 | -43.25 | -30 | -42.94 | 19.28 | -227.25 | Upgrade
|
| Income Tax Expense | - | - | -0.53 | -0.72 | 2.05 | -3.85 | Upgrade
|
| Net Income | -47.19 | -43.25 | -29.47 | -42.22 | 17.23 | -223.4 | Upgrade
|
| Net Income to Common | -47.19 | -43.25 | -29.47 | -42.22 | 17.23 | -223.4 | Upgrade
|
| Shares Outstanding (Basic) | 152 | 148 | 132 | 121 | 106 | 68 | Upgrade
|
| Shares Outstanding (Diluted) | 152 | 148 | 132 | 121 | 111 | 68 | Upgrade
|
| Shares Change (YoY) | 12.10% | 12.16% | 9.33% | 8.63% | 63.82% | 279.04% | Upgrade
|
| EPS (Basic) | -0.31 | -0.29 | -0.22 | -0.35 | 0.16 | -3.30 | Upgrade
|
| EPS (Diluted) | -0.31 | -0.29 | -0.22 | -0.35 | -0.31 | -3.30 | Upgrade
|
| Free Cash Flow | -33.19 | -32.83 | -21.13 | -48.83 | -7.82 | -38.72 | Upgrade
|
| Free Cash Flow Per Share | -0.22 | -0.22 | -0.16 | -0.41 | -0.07 | -0.57 | Upgrade
|
| Gross Margin | - | - | 74.26% | - | 50.89% | - | Upgrade
|
| Operating Margin | - | - | -271.36% | - | -57.42% | - | Upgrade
|
| Profit Margin | - | - | -294.66% | - | 34.90% | - | Upgrade
|
| Free Cash Flow Margin | - | - | -211.32% | - | -15.83% | - | Upgrade
|
| EBITDA | -46.73 | -45.13 | -26.57 | -52.52 | -28.25 | -49.11 | Upgrade
|
| EBITDA Margin | - | - | -265.70% | - | -57.22% | - | Upgrade
|
| D&A For EBITDA | 0.58 | 0.58 | 0.57 | 0.18 | 0.1 | 2.18 | Upgrade
|
| EBIT | -47.31 | -45.72 | -27.14 | -52.7 | -28.35 | -51.29 | Upgrade
|
| EBIT Margin | - | - | -271.36% | - | -57.42% | - | Upgrade
|
| Effective Tax Rate | - | - | - | - | 10.64% | - | Upgrade
|
Updated Nov 12, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.